Results 31 to 40 of about 243 (73)

Farnesyltransferase inhibitors decrease matrix-vesicle-mediated mineralization in SaOS-2 cells. [PDF]

Mol Biol Rep
Bürgel T, Diehl D, van Lier EC, Friedmann A, Hagemann A, Bachmann HS.   +5 more
europepmc   +1 more source

The effect of new atypical antipsychotic drugs on the expression of transcription factors regulating cytochrome P450 enzymes in rat liver. [PDF]

Pharmacol Rep
Danek PJ, Daniel WA.
europepmc   +1 more source

Chronic antipsychotic treatment exerts limited effects on the mania-like behavior of dopamine transporter knockdown mice. [PDF]

Behav Brain Res, 2021
Cope ZA, Kenton JA, Minassian A, Martin MV, Perry W, Bundgaard C, Arnt J, van Enkhuizen J, Geyer MA, Young JW.   +9 more
europepmc   +1 more source

Baricitinib Augments Lonafarnib Therapy to Preserve Colonic Homeostasis and Microbial Balance in a Mouse Model of Progeria. [PDF]

Aging Cell
Schroll M, Amar Y, Krüger P, Neuhaus K, Djabali K.   +4 more
europepmc   +1 more source

Hepatitis D Review: Challenges for the Resource-Poor Setting. [PDF]

Viruses, 2021
Lee AU, Lee C.
europepmc   +1 more source

Long-term sustained release Poly(lactic-co-glycolic acid) microspheres of asenapine maleate with improved bioavailability for chronic neuropsychiatric diseases. [PDF]

Drug Deliv, 2020
Zhai J, Wang YE, Zhou X, Ma Y, Guan S.
europepmc   +1 more source

Brief Report: HIV-1 Resistance Analysis of Participants With HIV-1 and Hepatitis B Initiating Therapy With Bictegravir/Emtricitabine/Tenofovir Alafenamide or Dolutegravir Plus Emtricitabine/Tenofovir Disoproxil Fumarate: A Subanalysis of ALLIANCE Data. [PDF]

J Acquir Immune Defic Syndr
D'Antoni ML, Andreatta K, Chang S, Cox S, Hindman JT, Avihingsanon A, Martin H, VanderVeen LA, Callebaut C.   +8 more
europepmc   +1 more source

The NLRP3 inhibitor Dapansutrile improves the therapeutic action of lonafarnib on progeroid mice. [PDF]

Aging Cell
Muela-Zarzuela I, Suarez-Rivero JM, Boy-Ruiz D, López-Pérez J, Sotelo-Montoro M, Del Mar Navarrete-Alonso M, Collado IG, Botubol-Ares JM, Sanz A, Cordero MD.   +9 more
europepmc   +1 more source

Asenapine versus olanzapine for the treatment of nausea and vomiting in patients with cancer: A retrospective study. [PDF]

Neuropsychopharmacol Rep
Kimura T, Kanai A, Muraoka H, Takahashi Y, Ara M, Inada K.   +5 more
europepmc   +1 more source

Optimal dose for the efficacy of asenapine in patients with schizophrenia: Real-world data. [PDF]

Neuropsychopharmacol Rep
Takekita Y, Hiraoka S, Iwama Y, Matsui D, Aoki N, Ogata H, Funatsuki T, Shimizu T, Murase Y, Koshikawa Y, Kato M, Kinoshita T.   +11 more
europepmc   +1 more source